<DOC>
	<DOCNO>NCT01863914</DOCNO>
	<brief_summary>Background Arteriovenous ( AV ) fistula common vascular access long-term hemodialysis end-stage renal disease ( ESRD ) patient . About 25 % patient diabetes mellitus . However , effect hyperglycemia vascular function arteriovenous fistula still remain unclear . Studies show blood flow AV fistula significantly reduce patient diabetes mellitus . Diabetic patient also require long period time maturation AV fistula , slightly high complication rate non-diabetic patient . Statins widely show mediate several important pleiotropic effect improvement vascular endothelial dysfunction , attenuation inflammatory response , stabilization atherosclerotic plaque , inhibition vascular smooth muscle proliferation , modulation procoagulant activity platelet function.Our experimental study diabetic animal demonstrate administration water-soluble statin rosuvastatin significantly improve fistula flow , vascular function luminal dilatation AV fistula diabetic rat suppression vascular oxidative stress inflammatory load . Study hypothesis The central hypothesis research project rosuvastatin mediate pleiotropic protective effect vascular endothelial function suppress regional pro-inflammatory reaction vasculature , therefore administration rosuvastatin perioperative period creation native AV fistula diabetic patient ESRD may potentiate vascular function reduce primary failure rate AV fistula .</brief_summary>
	<brief_title>Vascular Protective Effect Rosuvastatin Arteriovenous Fistula</brief_title>
	<detailed_description>Background In Taiwan , diabetic nephropathy second common cause end-stage renal disease ( ESRD ) , diabetic patient engender 12 % expense care dialysis non-diabetic patient . ESRD patient diabetes also frequently hospitalize due problem failure vascular access . Hemodialysis necessitate placement arteriovenous ( AV ) fistula , involve direct anastomosis radial/brachial artery cephalic vein . In United States , procedure create AV fistula treatment related complication account 20 % hospitalization dialysis patient cost US $ 100 million annually . Two major hurdle establish useable patent AV fistula dialysis primary failure ( failure fistula mature adequately dialysis ) long-term survival vascular access . The reported primary failure rate varies 20 50 % . It show reduction blood flow ( &gt; 15 % drop flow time ) critical factor premature failure AV fistula . Although blood flow venous site AV fistula also determine surround drain vein , blood pump arterial site important factor maintain sufficient fistula blood flow . However , limited study report effect arterial blood flow function patency AV fistula . More evidence show progressive failure AV fistula long-term use due development thrombosis ( ~80 % ) stenosis ( ~20 % ) . The mechanisms underlie failure AV fistula still poorly understood , , specific therapeutic approach increase lifespan fistula . Therefore , critical need experimental study seek understand basic mechanism primary failure progressive failure AV fistula diabetes mellitus . Creation AV fistula common vascular access ESRD patient , require long-term hemodialysis . In Taiwan , 25 % patient underlie diabetes mellitus . However , effect hyperglycemia vascular function arteriovenous fistula still remain unclear . Studies show blood flow AV fistula significantly reduce patient diabetes mellitus . Diabetic patient also require significantly long period time ( 2 month ) maturation AV fistula , slightly high complication rate non-diabetic patient . Diabetes mellitus show independent risk factor reduce blood flow native vessel arteriovenous fistula . Compared patient without diabetes access blood flow significantly low patient diabetes mellitus ( 788±580 vs 1054±681 ml/min , P = 0.002 ) . Patients diabetes mellitus require long time first use AV fistula patient without diabetes ( 4.4±2.9 vs 2.9±1.6 month , respectively , P= 0.02 ) . AV access-related complication need re-intervention high patient . Most recently , Previous study identify risk reduce primary patency AV fistula increase diabetes ( Hazard Ratio , 1.54 ; 95 % Confidence Interval , 1.14-2.07 ) . Presence diabetes also strong independent predictive factor reduce initial intra-access blood flow within 6 month creation AV fistula ( OR 3.5 , P = 0.001 ) . However , currently limit effective therapeutic strategy prevention loss primary patency improvement life expectancy AV access patient diabetes . 3-Hydroxy-3-methylglutaryl coenzyme A ( HMG-CoA ) reductase inhibitor ( statin ) one commonly prescribed agent control hyperlipidemia . Apart serum lipid-lowering property , statin widely show mediate several important pleiotropic effect , improvement vascular endothelial dysfunction , attenuation inflammatory response , stabilization atherosclerotic plaque , inhibition vascular smooth muscle proliferation , modulation procoagulant activity platelet function . Among pleiotropic effect , protective effect vascular endothelial function mostly highlight . In clinical setting , statin improve cardiovascular outcome patient atherosclerosis even population normal plasma cholesterol level . The improvement cardiovascular outcomes well correlate improve endothelial function upregulation endothelial nitric oxide synthase ( eNOS ) expression nitric oxide ( NO ) bioavailability follow treatment statin . At subcellular level , statin stabilize eNOS messenger ribonucleic acid ( mRNA ) , enhance eNOS enzymatic activity via phosphatidyl inositide ( PI ) 3 kinase signal pathway , reduce inflammatory response vasculature , inhibit Rho isoprenylation suppress oxidized- LDL-induced endothelin-1 expression . Statins also characterize enhance re-endothelialization damage vascular endothelium stimulate pre-existing endothelial cell mobilize bone marrow-derived endothelial progenitor cell ( EPCs ) . Collectively , stain restore vascular endothelial function mediate vascular protective effect independent lipid-lowering effect . Although beneficial pleiotropisms statin well document variety endothelial dysfunctional disorder , potential therapeutic effect maintain healthy , usable AV fistula subject diabetes mellitus previously demonstrate . According knowledge applicant , publish randomize control clinical study prospectively investigate vascular protective effect statins establishment AV fistula patient chronic kidney disease ( CKD ) ESRD . A long-term ( 987 day ) case-control study suggest patient receive statin therapy associate significantly high overall primary patency rate AV fistula 1 year ( 81.7 vs 66 % ) 2 year ( 71.5 vs 39.1 % ) . During past national science council ( NSC ) -funded year 2009-2011 , applicant undertook experimental study rat streptozotocin-induced diabetes , AV fistula create control diabetic animal . The diabetic rat receive either placebo rosuvastatin ( 10 mg/kg/d ) chow period 18 day ( 3 day creation AV fistula 14 operation ) . Circulating cluster differentiation ( CD ) 133+/vascular endothelial growth factor receptor ( KDR ) + EPCs determine 2 week creation AV fistula use flow cytometry . Vascular function AV fistula assess isometric force testing . The expression pro-inflammatory gene ( iNOS NADPH oxidase ) generation superoxide anion fistula examine . The result show number EPCs reduce diabetic rat , rosuvastatin significantly increase number circulate EPC . Reduced blood flow impair endothelium-dependent relaxation AV fistula animal diabetes significantly potentiate follow treatment rosuvastatin . Rosuvastatin also attenuate expression iNOS NADPH oxidase , generation superoxide anion fistula tissue isolate diabetic rat . These finding provide first important evidence demonstrate rosuvastatin improves blood flow endothelial function AV fistula subject diabetes mellitus attenuate activity pro-inflammatory gene generation superoxide anion remodel vasculature . Based fascinate encouraging finding , applicant proposes undertake clinical study translate experimental result diabetic patient CKD , schedule creation AV fistula hemodialysis . Central Hypothesis Specific Aims The central hypothesis research project rosuvastatin mediate pleiotropic protective effect vascular endothelial function suppress regional pro-inflammatory reaction vasculature , therefore administration rosuvastatin perioperative period creation native AV fistula diabetic patient ESRD may potentiate vascular function reduce primary failure rate AV fistula . Here , applicant proposes undertake three-year research project investigate therapeutic potential rosuvastatin establishment AV fistula patient diabetes mellitus . The applicant opts test propose effect rosuvastatin diabetic patient . The long-term aim project develop clinical feasible , endothelium-targeted therapeutic strategy durable AV fistula human subject necessitates hemodialysis . To achieve research goal applicant propose study follow specific aim : 1 . Administration rosuvastatin protect endothelial function AV fistula restore blood flow rate shunt diabetic patient ESRD , thereby improve primary patent rate early maturation fistula . 2 . Administration rosuvastatin improve vascular function AV fistulas diabetic patient ESRD , therefore reduce overall shunt-related complication rate requirement surgical re-interventions . 3 . Administration rosuvastatin associate reduction systemic pro-inflammatory response oxidative stress ( level proinflammatory cytokine mediator circulation ) diabetic patient ESRD . On hand , administration rosuvastatin may mobilize bone marrow-derived EPCs systemic circulation , number circulate endothelial progenitor may provide prognostic value outcomes AV fistula . 4 . Administration rosuvastatin reduces overall perioperative cardiovascular morbidity diabetic patient ESRD . 5 . Administration rosuvastatin increase incidence statin-related complication ( myopathy , abnormal liver function neurologic deficit ) diabetic patient ESRD .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Arteriovenous Fistula</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Patients diabetes mellitus ( postprandial blood sugar &gt; 140 mg/dl ) 2 . Patients endstage kidney disease propose undertake chronic hemodialysis 3 . Patients age 1865 year 4 . The fistula construct forearm ( radiocephalic fistula ) . 1 . Preoperative blood sugar level &gt; 250 mg/dl recent HbA1c &gt; 10 % 2 . Recent treatment statin within 2 week evaluation clinical trial 3 . Advanced liver disease 4 . Chronic alcoholism 5 . Congestive heart failure 6 . Coronary disease require permanent statin therapy 7 . Malignancy hematologic disorder 8 . Pregnancy breastfeed 9 . Past history creation AV fistula 10 . Scheduled general anesthesia 11 . Emergent operation 12. peripheral arterial occlusion disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ESRD</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Endothelial progenitor cell</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>rosuvastatin</keyword>
</DOC>